Unibest
← Back to patent-cliff list

Ritlecitinib tosylate

Tier C — Watch / trade

Ritlecitinib tosylate

Pfizer Inc.
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets：JAK3, TEC kinase family

Brand：Litfulo, LITFULO

Indications (approved)：Alopecia areata

Regional status

US
Approved
2023-06-23
EU
Approved
2023-09-15
China
Approved
2023-10-18
Japan
Approved
2023-06-26

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 9 · Total yield /
PF-066516001792180-81-4PF-06651600-0013430-14-6PF-06651600-002323578-37-6PF-06651600-0031150618-39-5PF-06651600-0042101218-65-7PF-06651600-0051207853-21-1PF-06651600-0061207947-49-6PF-06651600-00790213-66-4PF-06651600-0082042650-65-5PF-06651600-009—PF-06651600-0101792180-81-4API · Ritlecitinib tosylate
CodeCAS No.Intermediate
PF-066516001792180-81-4Available1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
PF-06651600-0013430-14-6Available6-methylpyridin-3-amine
PF-06651600-002323578-37-6Availabletert-butyl (6-methylpyridin-3-yl)carbamate
PF-06651600-0031150618-39-5Availabletert-butyl (6-methylpiperidin-3-yl)carbamate
PF-06651600-0042101218-65-7Availablebenzyl 5-((tert-butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate
PF-06651600-0051207853-21-1Available(2S,5R)-benzyl 5-((tert-butoxycarbonyl)amino)-2-methylpiperidine-1-carboxylate
PF-06651600-0061207947-49-6Available(2S,5R)-benzyl 5-amino-2-methylpiperidine-1-carboxylate
PF-06651600-00790213-66-4Available2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine
PF-06651600-0082042650-65-5Available(2S,5R)-benzyl 5-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidine-1-carboxylate
PF-06651600-009-N-((3R,6S)-6-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
PF-06651600-0101792180-81-4Available1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Frequently asked questions

What are the approved indications of Ritlecitinib tosylate?

Approved indications include: Alopecia areata.

When does the Ritlecitinib tosylate patent expire?

No public expiry year is available for Ritlecitinib tosylate yet; this page updates once verified.

How many synthesis routes are recorded for Ritlecitinib tosylate?

1 synthesis routes are recorded; the shortest is 9 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Ritlecitinib tosylate intermediates?

9 intermediate CAS of Ritlecitinib tosylate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Ritlecitinib tosylate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27